Best Weight Loss Medications in 2026: Every FDA-Approved Pill and Shot Compared

There is no single best weight loss medication for everyone, but on average weight loss in clinical trials, weekly tirzepatide (Zepbound) leads the FDA-approved options, followed by weekly semaglutide (Wegovy) and the two GLP-1 pills, the Wegovy pill and Foundayo (orforglipron). The best choice for a given person depends on their health history, whether they want a pill or an injection, side effects, and what they will actually pay each month.

Below is every FDA-approved option for long-term weight management in adults, the main trial result for each, current self-pay prices from the manufacturers, and the questions that usually decide which one a clinician prescribes.

The FDA-Approved Weight Loss Medications in 2026

NIDDK lists six medicines approved for long-term weight management: orlistat (Xenical, and the lower-dose Alli sold over the counter), phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), liraglutide (Saxenda), semaglutide injection (Wegovy) and tirzepatide (Zepbound). Phentermine on its own is approved only for a few weeks of use. Setmelanotide (Imcivree) is approved only for obesity caused by specific rare genetic conditions confirmed by testing.

That NIDDK page was last reviewed in June 2024, so it does not include the two newer pills. The FDA approved the once-daily Wegovy pill (oral semaglutide) on December 22, 2025, and Foundayo (orforglipron), a once-daily pill from Eli Lilly, on April 1, 2026. Both are approved for adults with obesity, or overweight with at least one weight-related condition, alongside a reduced-calorie diet and more physical activity.

The general adult criteria NIDDK describes are a BMI of 30 or higher, or 27 or higher with a weight-related problem such as high blood pressure or type 2 diabetes. A clinician still decides whether a specific drug fits, based on your other conditions and medicines.

Which Weight Loss Medication Works Best?

In SURMOUNT-1, a 72-week trial in 2,539 adults with obesity and without diabetes, weekly tirzepatide at 5, 10 or 15 mg produced average weight loss of roughly 15% to 21% of starting weight, compared with about 3% on placebo. In STEP 1, a 68-week trial in 1,961 adults without diabetes, weekly semaglutide 2.4 mg produced an average change of -14.9%, compared with -2.4% on placebo.

Those were separate trials, so their numbers cannot be lined up as a contest. SURMOUNT-5 is the direct comparison: 751 adults with obesity and without type 2 diabetes received the maximum tolerated dose of either tirzepatide or semaglutide for 72 weeks. Average weight change was -20.2% with tirzepatide and -13.7% with semaglutide. Gastrointestinal side effects were the most common in both groups, mostly mild to moderate and mainly during dose increases.

The older pills produce smaller average losses. NIDDK reports that after one year, adults taking a weight management medication with a lifestyle program lost about 3% to 12% more of their starting weight than people using lifestyle changes alone, depending on the drug. It also notes that most weight loss happens in the first six months.

What Is the Best Weight Loss Pill?

For people who do not want injections, the two GLP-1 pills now have the strongest trial results among oral options. Neither has been compared head to head with the other in a published trial, and their main trials used different populations and lengths, so treat the numbers below as separate results rather than a ranking.

• •Wegovy pill (oral semaglutide 25 mg): in OASIS 4, a 64-week trial of 307 adults with obesity or overweight and a weight-related condition, people who stayed on treatment lost about 16.6% of body weight versus 2.7% on placebo. Counting everyone regardless of whether they kept taking it, the figures were 13.6% versus 2.4%. It is also approved to reduce the risk of heart attack, stroke and cardiovascular death in adults with established cardiovascular disease and overweight or obesity.
• •Foundayo (orforglipron): in ATTAIN-1, a 72-week trial of 3,127 adults with obesity and without diabetes, average weight change was -11.2% on the highest dose studied versus -2.1% on placebo. Lilly reports 12.4% for the highest dose when only people who stayed on treatment are counted. Foundayo can be taken at any time of day with no food or water restrictions. The Wegovy pill has its own administration instructions, so check its label or ask the pharmacist.

Among older pills, Qsymia and Contrave are approved for long-term use, and orlistat works in the gut to reduce fat absorption. Each has its own exclusions: NIDDK notes Qsymia should be avoided with glaucoma, hyperthyroidism or recent MAOI use, and Contrave with uncontrolled high blood pressure, seizures, eating disorders or frequent opioid use. These can be options when a GLP-1 medicine is not suitable or not affordable.

What Each Option Costs Without Insurance

Both manufacturers now sell branded medicine directly to cash-paying patients. These are the prices published by Novo Nordisk and Eli Lilly on October 25, 2026, for cash-paying patients. They exclude telehealth membership or visit fees, and the companies say they can change or end the offers at any time.

• •Wegovy pill: $149 for 1.5 mg, $199 for 4 mg, and $299 for the 9 mg and 25 mg maintenance doses.
• •Wegovy injection: $349 for every standard dose. New patients can get the two lowest doses for $199 for the first two monthly fills under an offer that runs through December 31, 2026, after which the price is $349. The higher-dose Wegovy HD 7.2 mg is listed at $399.
• •Zepbound: $299 for 2.5 mg and $399 for 5 mg. The 7.5 mg to 15 mg doses are $449 only if you refill within 45 days of the previous fill; otherwise the listed regular price is $499 for 7.5 mg and $699 for 10 mg, 12.5 mg and 15 mg. Lilly defines a month as 28 days, and the self-pay card expires December 31, 2026.
• •Foundayo: $149 for the 0.8 mg starting dose and $199 for 2.5 mg through LillyDirect, with higher doses at $299 when refilled within 45 days.

Starting doses are the cheapest, so the price you will pay after a few months of dose increases matters more than the first fill. Self-pay spending generally does not count toward an insurance deductible, and the manufacturer cards exclude people on Medicare, Medicaid and other government plans. Check the current price on the manufacturer's page before you start.

Side Effects and Safety Warnings

Nausea, diarrhea, vomiting and constipation are the most common side effects of the GLP-1 medicines in their trials, and they tend to appear while the dose is being raised. In STEP 1, 4.5% of people on semaglutide stopped because of gastrointestinal effects, compared with 0.8% on placebo. In ATTAIN-1, 5% to 10% of people on orforglipron stopped because of side effects, compared with 3% on placebo.

Liraglutide, semaglutide and tirzepatide should not be used by people with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2, a warning based on thyroid tumors seen in rodent studies. Novo Nordisk also lists pancreatitis, gallbladder problems, dehydration leading to kidney problems, and depression or suicidal thoughts among the serious possible effects of the Wegovy pill. NIDDK advises against taking weight management medicines during pregnancy, when planning a pregnancy, or while breastfeeding.

Compounded GLP-1s Are Not on This List

Many online programs sell compounded semaglutide or tirzepatide at prices below the branded products. The FDA states that compounded GLP-1 drugs are not FDA-approved and that it does not review them for safety, effectiveness or quality before they are sold. It has received reports of dosing errors, some requiring hospitalization, and warns about counterfeit products and items labeled "for research purposes" sold for human use. The trial results above apply only to the approved branded medicines.

How a Clinician Chooses Between Them

1. 1.Health history: thyroid cancer history, pancreatitis, glaucoma, seizures, eating disorders and pregnancy plans can rule specific drugs out.
2. 2.Other conditions: established heart disease may point toward Wegovy, which carries a cardiovascular risk reduction indication; type 2 diabetes changes which drugs and doses are considered.
3. 3.Pill or injection: some people will only take a pill, and Foundayo has no food or water restrictions, which may make a daily routine easier.
4. 4.Cost at the maintenance dose: compare what you will pay once the dose is increased, plus any telehealth fees, not just the first month.
5. 5.Response: NIDDK notes that a clinician will probably advise stopping if you have lost less than 5% of your weight after 12 weeks at the full dose.

Frequently Asked Questions

What is the most effective weight loss medication? Among FDA-approved options, tirzepatide (Zepbound) produced the largest average weight loss in its trials, and in the head-to-head SURMOUNT-5 trial it outperformed semaglutide injection on average (-20.2% versus -13.7% at 72 weeks). That does not make it the right drug for everyone; tolerability, cost and health history all matter.

What is the best weight loss pill on the market? The Wegovy pill and Foundayo are the only GLP-1 pills approved for weight management. The Wegovy pill showed larger average loss in its own trial, while Foundayo has no food or water timing rules. Older pills such as Qsymia and Contrave remain approved options with smaller average effects.

Will I regain weight if I stop? NIDDK says people will probably regain some weight after stopping a weight management medicine. These drugs are approved for long-term use and can be continued while they help and side effects are acceptable, a decision to make with your clinician.

Can I get these medicines online? Yes. Licensed telehealth clinicians can prescribe them after an assessment, and both manufacturers sell self-pay supplies through their own pharmacy programs. Make sure the prescription is filled by a state-licensed pharmacy and that you know exactly which product you are getting.